Drug Approval | May 25, 2026
Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
The therapy is suited for patients with severe valve leakage who face elevated surgical risk due to advanced age, frailty, or multiple medical complications
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
At the institute's 42nd convocation ceremony, Union Minister described its eight-institution MoU initiative as a unique collaborative effort that brings together premier national institutions to create a synergistic research ecosystem
New facility ‘Amber Wing’ adds 55 beds and strengthens surgical, cardiac, robotic and preventive care infrastructure for women in Mumbai
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
